ENTERA BIO IS-0000769 Cash Flow Conversion Efficiency
ENTERA BIO IS-0000769 cash flow conversion efficiency. Based on the latest financial reports, ENTERA BIO IS-0000769 (5DT) has a cash flow conversion efficiency ratio of -0.477x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.46 Million ≈ $-4.05 Million USD) by net assets (€7.27 Million ≈ $8.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ENTERA BIO IS-0000769 (2021–2025)
Cash flow conversion efficiency of ENTERA BIO IS-0000769 from 2021 to 2025. This chart illustrates how ENTERA BIO IS-0000769's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest ENTERA BIO IS-0000769 stock price today for real-time trading data and today's change.
ENTERA BIO IS-0000769 Cash Flow Conversion Ratio Explained
ENTERA BIO IS-0000769 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ENTERA BIO IS-0000769 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ENTERA BIO IS-0000769 ranked by their cash flow conversion efficiency. Also see ENTERA BIO IS-0000769 (5DT) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Citi Trends Inc
NASDAQ:CTRN
|
0.167x |
|
CCCG Real Estate Corp Ltd
SHE:000736
|
-0.314x |
|
ITAB Shop Concept AB ser. B
ST:ITAB
|
-0.002x |
|
Shenzhen Bestek Technology Co Ltd
SHE:300822
|
0.014x |
|
Gotland Rederi AB Series A
ST:GOTL-A
|
0.058x |
|
Zhengyuan Geomatics Group Co Ltd
SHG:688509
|
0.007x |
|
Vietnam Construction and Import Export JSC
VN:VCG
|
-0.005x |
|
Elevra Lithium Limited
AU:ELV
|
-0.051x |
Annual Cash Flow Conversion Efficiency for ENTERA BIO IS-0000769 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ENTERA BIO IS-0000769 from 2021 to 2025. Review 5DT free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €13.10 Million ≈ $15.32 Million |
€-7.37 Million ≈ $-8.62 Million |
-0.563x | +33.33% |
| 2024-12-31 | €8.08 Million ≈ $9.45 Million |
€-6.82 Million ≈ $-7.97 Million |
-0.844x | -19.89% |
| 2023-12-31 | €10.39 Million ≈ $12.14 Million |
€-7.31 Million ≈ $-8.55 Million |
-0.704x | +33.81% |
| 2022-12-31 | €11.75 Million ≈ $13.74 Million |
€-12.50 Million ≈ $-14.61 Million |
-1.063x | -164.76% |
| 2021-12-31 | €22.57 Million ≈ $26.38 Million |
€-9.06 Million ≈ $-10.60 Million |
-0.402x | -- |
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more